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ABSTRACT 
&
&
The process of generating muscle fibers, also called myogenesis, is 
a perfectly orchestrated and continuous mechanism that leads to the 
formation of multinucleated myofibres capable of contraction. 
Myogenesis is a highly regulated process involving the expression 
of muscle specific transcription factors inducing the production of 
appropriate developmental stage-specific transcripts. 
In the last years our group identified several non-coding RNAs 
(ncRNAs) with a specific role in both muscle differentiation and 
muscle degenerative pathologies. Among them we studied a 
microRNA, miR-31, expressed at high levels in muscle affected by 
Duchenne muscular dystrophy (DMD).  We were able to 
demonstrate the importance of this miRNA in the differentiation 
process and its ability to repress, by targeting the mRNA 3’ UTR, 
the expression of Dystrophin, a protein that has a key role in muscle 
fibres contraction and integrity.  
Recently, our group also discovered a long non-coding RNA 
(lncRNA), named linc-MD1, cross-regulating specific mRNAs by 
competing for miRNA binding via their miRNA recognition motifs. 
These studies opened the intriguing possibility that lncRNA-based 
mechanisms might influence different sets of transcripts during the 
execution of crucial metabolic pathways, as cellular differentiation 
programs. 
Based on these assumptions my research project has its main focus 
on the contribution of non-coding RNAs (ncRNAs) in muscle 
differentiation. By combining advanced high-throughput RNA 
sequencing with cellular and molecular biology techniques I have 
worked to get a more comprehensive catalogue of muscle specific 
lncRNAs and to decipher how these molecules regulate gene 
expression and chromatin dynamics. Once identified these new 
player in muscle physiology we will move towards understanding 
their functional implication in muscle differentiation and 
pathologies. 
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Studying non-coding RNAs in murine muscles, I also identified two 
lncRNAs deriving from the miR-31 locus, located on the fourth 
chromosome (linc-31D and linc-31P).  
These two lncRNAs have a different structure and a different 
localization in the intracellular compartments. Linc-31P is localized 
in the nucleus, associated with the chromatin while linc-31D is 
found in the cytoplasm.  RNAi and over-expression experiments 
allowed me to demonstrate that linc-31D has a role in promoting the 
switch between proliferation and differentiation. 
In the human genome the miR-31 locus is located on chromosome 9 
and I found, once again, two lncRNAs transcribed from two 
different TSS. I measured their levels in WT and DMD primary 
myoblasts reaching the conclusion that they are expressed, as in 
mouse, at high levels in proliferating conditions. Similarly to 
mouse, the induction of the differentiation parallels a decrease in 
the two isoforms’ levels in WT cells. 
Viceversa, the lncRNA levels remain quite high in DMD conditions 
where the myogenetic process is delayed, corroborating, once again, 
our hypothesis of a role for these lncRNAs in promoting the switch 
between proliferation and differentiation. 
 
.  
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INTRODUCTION 
Skeletal muscle development 
The process of generating muscle fibers, also called myogenesis, is 
a perfectly orchestrated and continuous mechanism that leads to the 
formation of a multinucleated myofibres capable of contraction 
(Figure 1).  
Myogenesis can be divided into several phases, highly regulated by 
the coordinated expression of regulatory RNAs, chromatin-
remodeling elements and a family of transcription factors known as 
myogenic regulatory factors (MRFs) that are able to control the 
production of appropriate developmental stage-specific transcripts 
(Tajbakhsh 2009) (figure 1). 
Proteins in the MRF family share a homologous basic Helix-Loop-
Helix (bHLH) domain that is able to bind DNA to the consensus E-
box sequence CANNTG, that is found in the promoter sequence of 
many muscle-specific genes and to form heterodimers with the E-
protein family of transcription factors (Tapscott 2005)  
During embryogenesis, skeletal myogenic progenitors are derived 
from the somites originating from the paraxial mesoderm (Aulehla 
and Pourquié 2006) and their specification to a muscular lineage is 
guided by the combinatorial action of extrinsic factors, either 
positive and negative signals, emanated from adjacent cells, and 
MRFs inside the nucleus (Parker et al. 2003); in particular, MyoD 
(Ishibashi et al. 2005, Tapscott 2005, Cao et al. 2006), Myf5 
(Ishibashi et al. 2005), Myogenin (Cao et al. 2006) and Mrf4 
(Kassar-Duchossoy et al. 2004) that have a well-characterized role 
in directing the process.  
MyoD, Myf5 and Mrf4 are responsible of determining skeletal 
muscle cell identity and, in particular, it has been demonstrated that 
either MyoD or myf5 is required for the formation of skeletal 
muscle, and, even if mice lacking both of them were born alive, 
they were immobile and died soon after birth (Rudnicki et al. 1993). 
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In double-mutant mice, progenitor cells remain multi-potent and 
can change their fate (Tajbakhsh et al. 1996, Kablar et al. 1999) but 
in their absence MRF4 is able to determine skeletal muscle identity, 
that, on the contrary, is completely lost when, in addition to MyoD 
and myf5, MRF4 is absent too (Kassar-Duchossoy et al. 2004).  
MRFs control over the specification process is so strong that their 
forced expression into a variety of non-muscle cells is able to 
activate the myogenesis (Braun et al. 1989, Edmondson and Olson 
1989, Rhodes and Konieczny 1989), and, in some cases, to lead to 
the formation of terminally differentiate muscle cells (Davis et al. 
1987).  
Proliferating cells expressing MyoD and Myf5 are called myoblasts 
and are set to exit the cell cycle and to start the differentiation 
process undergoing morphological changes, at this point cells begin 
to express MRFs and myogenin that are more directly involved in 
this phase of the process and trigger the expression of late 
differentiation myogenic marker such as myosin heavy chain 
(MHC) and muscle creatine kinase (MCK).  
Myogenin, as the other MRFs has a crucial role in the muscle 
development and mice that are lacking this factor, are able to 
survive the fetal development but die shortly after birth showing a 
severe reduction of skeletal muscles (Hasty et al. 1993). 
In the final stages of differentiation, cells expressing structural 
proteins start to fuse forming a multinucleated syncytium and 
finally generating a mature fiber capable of contraction. This 
results, at the end of the embryonic development, in the formation 
of innervated, vascularized and contractile muscle tissues.  
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Figure 1 – Hierarchy of transcription factors orchestrating the 
progression through the myogenic lineage. Muscle progenitors 
that are involved in embryonic muscle differentiation skip the 
quiescent satellite cell stage and directly become myoblasts. Some 
progenitors remain as satellite cells in postnatal muscle and form a 
heterogeneous population of stem and committed cells. Activated 
committed satellite cells (Myoblasts) can eventually return to the 
quiescent state. Six1/4 and Pax3/7 are master regulators of early 
lineage specification, whereas Myf5 and MyoD commit cells to the 
myogenic program. Adapted from (Bentzinger et al. 2012). 
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Satellite cells and adult myogenesis. 
During the muscular tissue development, a pool of cells, named 
satellite cells for their sub-laminar location, fails to enter the 
differentiation process, remaining associated to the periphery of 
skeletal muscle myofiber, in a quiescent state (Mauro 1961). 
Satellite cells are considered to be the main players in the 
regenerative processes of the muscular tissue. Skeletal muscle has, 
in fact, the incredible ability to respond to damages and to repair 
injuries, reforming healty tissue: this regeneration is largely due to 
interplay between the satellite cells and their niche in the muscle. 
Satellite cells are quite recognizable, thanks to a characterized 
series of transcription factors that are expressed at high levels. 
In adult skeletal muscle, in fact, most of satellite cells are found to 
express the paired domain transcription factors Pax7 (Seale et al. 
2000) and Pax3 (Buckingham et al. 2003), and the already 
described MRF, myf5 (Cornelison and Wold 1997).  
Once activated, in response to the deterioration of the basal lamina,  
a pool of cells exit from their quiescent state and enter the cell 
cycle. Proliferating satellite cells follow two different destinies, a 
group return to quiescence to maintain the satellite cell pool 
reservoir, which is critical for the long-term health of the tissue, and 
another group is formed by cells, originating from symmetric 
division, that are set to become myogenic precursor cells (Collins et 
al. 2005) (figure 2). This newly originated myoblasts start to 
express MyoD and to down-regulate Pax7 entering in a path that 
closely resemble the one followed by myoblast originated during 
the embryonic development (Yin et al. 2013). 
Figure 2 – Proliferation and commitment of the satellite cell 
population. (Yin et al. 2013) 
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Duchenne Muscular Distrophy 
Genetic diseases affect the population worldwide in all stages of life 
with different consequences and clinical outcomes; among them 
Muscular Dystrophies form the most common class of single-gene 
disorders affecting millions of people and causing progressive 
wasting and weakness of skeletal muscle.  
Duchenne Muscular Distrophy (DMD) is the most severe form of 
muscular dystrophy and the most common, affecting one in 3500 
male births. This fatal disease, is an X-linked recessive disorder 
caused by mutations in the dystrophin gene (dmd) that encodes for a 
427 kDa protein that has the very delicate and important role of 
connecting the actin in the cytoskeleton to the extracellular matrix 
in muscle fibers by forming interactions with a protein complex 
named the dystrophin-associated protein complex (DAPC) 
(Matsumura and Campbell 1994)(figure 3). The DAPC has a major 
role in protecting the muscle fiber and maintaining the integrity of 
the sarcolemma (Ervasti and Sonnemann 2008) and moreover its 
correct localization influences the intracellular nitric oxide (NO) 
pathway (Brenman et al. 1995). 
When the dystrophin level in the cell is reduced or the protein is 
completely absent, the entire complex is delocalized causing severe 
sarcolemma fragility and leading to breakages of the muscle   
membrane in response to contractions. 
In addition to that, the disruption of the association between the 
sarcolemmal neuronal Nitric Oxide Synthase (nNOS) and DAPC 
leads to impaired NO production in dystrophic muscles; this cause 
the alteration of the HDAC2 S-nitrosylation and its chromatin 
association, deregulating the expression of a specific subset of 
microRNA genes crucial in DMD physiopathology (Cacchiarelli et 
al. 2010).  
In DMD patients the damages in the tissue activate the quiescent 
pool of satellite cells and injuries are, at first, repaired, thanks to the 
activity of cells that fuse to existing myotubes but the regenerative 
process is, unfortunately, largely inefficient compared to great 
extent of the damages and the satellite pool soon loose its potential 
and the muscle fiber is subject to severe degeneration causing 
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chronic inflammation, susceptibility of the tissue to oxidative stress 
and finally necrosis. The necrotic tissue is slowly replaced by 
adipose and fibrotic infiltrations making the damages permanent. 
DMD patients soon loose the ability to walk or simply stand and are 
forced to a wheel chair by the age of 12. 
The most affected skeletal muscle is the diaphragm where the tissue 
degeneration leads to the death of the patient due to respiratory 
failure but the pathology also affects severely the cardiac muscle, 
and more than 90% of DMD patients develop cardiomyopathies 
(Nigro et al. 1990). 
 
 
&
Figure 3 - Dystrophin binds to the DAPC at the sarcolemma. 
Dystrophin, which is localized at the sarcolemma, has a long 
central rod domain made up of spectrin repeats, which are 
interspersed with hinge regions. The C-terminus is preceded by a 
cysteine-rich domain and binds to the dystrophin-associated protein 
complex (DAPC). The DAPC is comprised of sarcoplasmic proteins 
(α-dystrobrevin, syntrophins and neuronal nitric oxide synthase 
(nNOS)), transmembrane proteins (β-dystroglycan, the 
sarcoglycans, caveolin-3 and sarcospan) and extracellular proteins 
(α-dystroglycan and laminin). (Davies and Nowak 2006)  
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Exon skipping approaches 
 
DMD, is an ideal candidate for gene therapy, as it derives from 
single-gene mutations affecting the dmd gene; the majority of 
patients, carry mutations that disrupt the reading frame of the 
dystrophin gene, generating a truncated unstable dystrophins 
lacking the C-terminal bridging domain responsible for the 
connection to the DAPC (Aartsma-Rus et al. 2006). 
Interestingly, there is another form of muscular dystrophy caused 
by mutations in the dmd gene: the Becker muscular dystrophy 
(BMD) (Koenig et al. 1989), a milder pathology that is frequently 
due to mutations that interest the gene maintaining its correct 
reading frame. In BMD there is the production of an internally 
truncated dystrophin protein that only lacks part of the central rod 
domain and maintain a partial functionality (Hoffman et al. 1988).  
These observations have led to the formulation of the reading-frame 
rule to explain the phenotypic differences between BMD and DMD 
patients (Monaco et al. 1988), and to the idea that it is possible to 
realize, using an exon-skipping strategy, a dystrophin protein with a 
partially deleted flexible central rod domain. This therapeutic 
approach is based on the use of antisense oligonucleotides (AONs) 
capable to interfere with the splicing mechanism targeting specific 
splice sites or splicing regulatory regions (enhancers) on the pre-
mRNA, hiding them from the splicing machinery and causing their 
exclusion from the mature mRNA (figure 4A). Many studies 
showed a successful dystrophin reading-frame restoration in the 
mdx model mouse, a naturally occurring dystrophin-deficient 
mutant that was first described in 1984 in a colony of C57BL/10 
mice (C57BL/10ScSnJ) (Willmann et al. 2009) and that carrying a 
premature stop codon in its exon 23, has been widely used to study 
the DMD pathology (Dunckley et al. 1998, Wilton et al. 1999, 
Mann et al. 2001). Exon skipping approaches also proved to be 
effective on DMD patient derived muscle cells (van Deutekom et al. 
2001). Thanks to the successes obtained both in vitro and in vivo, 
AONs-based therapies, aimed to the skipping of human exon 51, 
have been tested in clinical trials based both on intramuscular (van 
Deutekom et al. 2007, Kinali et al. 2009) and systemic (Cirak et al. 
Dottorato&di&ricerca&in&Genetica&e&Biologia&Molecolare&
&
Pag&15&&
2011, Goemans et al. 2011) administration of molecules chemically 
modified to improve their stability. These studies demonstrated that 
exon skipping for DMD is a safe approach and that is successful in 
increasing dystrophin levels but also showed that there is a 
significant obstacle to overcome: these modified AONs are cleared 
rapidly from the circulation and have some difficulties in reaching 
all the muscular districts in the body. A strategy, aimed to the in-
situ production of AONs, was developed to avoid reiterating 
administrations and to improve therapeutic efficiency; this approach 
is based on the use of chimeric small nuclear RNAs (snRNAs) that 
have been designed to shuttle the antisense molecule (figure 4B). 
Good results, in term of construct delivery and dystrophin rescue, 
have been obtained, using viral vector-mediated U1snRNA; the 
approach was, in fact, successful both in DMD cultured cells (De 
Angelis et al. 2002, Incitti et al. 2010, Cazzella et al. 2012) and in 
the mdx mouse (Denti et al. 2006) that has also been used to test the 
long term benefits of the treatment (Denti et al. 2008). 
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  Figure 4  Example of exon-skipping strategy.! 
&
A) Deletion of exon 50 in DMD gene results in an out-of-frame 
mRNA transcript and a prematurely aborted dystrophin synthesis. 
B) Employing of antisense molecules against exon 51 splice sites 
produce an in frame mRNA transcript resulting in a shortened 
BMD-like dystrophin protein. 
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Non-coding RNAs 
One of the great paradoxes in molecular biology is the relationship 
between the biological complexity across eukaryotes and the 
number of protein-coding genes and their extent. During the 
evolution, in fact, the number of protein coding genes has remained 
quite stable but, on the contrary, a larger amount of non-coding 
DNA is found in the genome of complex organism.  
These sequences have been considered, for years, to be genetically 
inert fragments and have been called “junk DNA” that was 
considered as “tolerated” more easily by complex organisms. With 
the genome sequencing era and the technological advances that 
allowed a deep analysis of the trascriptome, came the realization 
that the vast majority of the complex organisms genome is 
transcribed to produce a large number of ncRNAs that have been 
found to be antisense, intergenic or overlapping with protein-coding 
genes and whom transcription is regulated trough evolution. 
Rapid progress in characterizing these ncRNAs has lead to the 
identification of many subclasses that, even sharing the common 
function of regulating gene expression, vary widely in size, 
sequence and mechanism-of-action. It is now very clear that they 
play a major role in development of organisms and in many cellular 
pathways and that if mis-regulated can have a significant role in 
many diseases.  
The first characterized ncRNAs, ribosomal RNAs (rRNAs) and 
transfer RNAs (tRNAs) account for more than 95% of cellular RNA 
content. Other ncRNAs are broadly classified on the basis of length. 
Molecules shorter than 200 nucleotides are classified as short 
ncRNAs and include microRNAs, small nucleolar and nuclear 
RNAs, piwi-interacting RNAs, and small interfering RNAs. 
Molecules longer than 200 nucleotides have been arbitrary grouped 
together and called long non-coding RNAs (lncRNAs). 
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Micro-RNAs 
 
Micro-RNAs (miRNAs) are small, evolutionarily conserved 
noncoding RNAs, of ≈22nt in length, that are transcribed, with few 
exceptions, by RNA polymerase II (Cai et al. 2004, Lee et al. 2004). 
This class of transcripts shows a peculiar genomic localization as 
they can be exonic, intronic or intergenic and be in found 
monocistronic or polycistronic units (Morlando et al. 2008, 
Ballarino et al. 2009). 
They are initially transcribed in a hairpin-shaped molecule called 
pri-miRNA that undergoes a first endonucleolitic cleavage by the 
microprocessor complex, formed by Drosha and DGCR8, which 
produces a 70 nucleotides hairpin RNA called pre-miRNA, which 
can, thanks to the exportin 5, be exported to the cytoplasm and 
processed by Dicer to yield a duplex RNA of 22-23 nucleotides. 
Only one filament of the duplex, will then be chosen to be loaded in 
the RNA-induced silencing complex (RISC) as mature miRNA, 
while the other strand, the miRNA* will be degradated (Bartel and 
Chen 2004) (figure 5). 
miRNAs have the ability of regulating gene expression through a 
sequence-specific interaction with a target mRNA, usually at its 3’ 
untranslated region (UTR), resulting in translational repression or 
mRNA destabilization (He and Hannon 2004).  
Some miRNAs exert their effects through a strong repression of a 
relatively small number of targets but it is more frequent to find 
miRNAs targeting hundreds of mRNA realizing a complex network 
of interactions that achieve a fine-tuning in gene expression. 
Recent studies have described new types of regulations mediated by 
this class of ncRNAs such as translation up-regulation (Vasudevan 
et al. 2007) and heterochromatin formation (Kim et al. 2008); in 
addition to that, small RNAs have been described to be directly 
involved in transcription processes through sequence-specific 
interactions with promoter elements of target genes (Schwartz et al. 
2008) adding another layer of complexity to the cell regulatory 
mechanisms.  
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Figure 5- miRNA biogenesis  
MicroRNAs  are processed from RNA polymerase II (RNAPII)-
specific transcripts of independent genes or from introns of 
protein-coding genes. 
In the canonical pathway, primary precursor (pri-miRNA) 
processing occurs in two steps, catalyzed by two members of the 
RNase III family of  enzymes, Drosha and Dicer, operating in 
complexes with dsRNA-binding proteins (dsRBPs). (Krol et al. 
2010) 
!
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Long non-coding RNAs  
 
LncRNAs are molecules with little to none protein encoding 
capacity that have been grouped together even if they show a great 
heterogeneity in size (from 200 nucleotides to beyond 10 
kilobases), functions localization and role in the cell.  
These transcripts, normally expressed at lower levels compared 
with   protein-coding RNAs, are generally transcribed by 
conventional promoters by RNA polymerase II, often spliced and 
can be either polyadenylated or not, and can be localized both in the 
nuclear compartment or in the cytoplasm (Ponting et al. 2009) 
exerting different functions in the cell. 
It is estimated that thousands of lncRNAs are encoded in the human 
genome, expressed mostly in tissue-specific patterns, they are 
versatile molecules that are able to interact physically and 
functionally with DNA, other RNAs and proteins through direct 
base pairing or through functional domains, created thanks to the 
many possibilities offered by their folding ability. These properties 
endow lncRNAs with an incredible range of capabilities and 
mechanisms of action (Paralkar and Weiss 2013) (figure 6).  
One of the first characterized lncRNAs, Xist, is a perfect example 
of the role these molecules can play in epigenetic processes; once 
transcribed from one of the X chromosome in female’s XX cells, 
Xist coats that chromosome itself and recruits repressive complexes 
to condense the chromatin and silence it in a process termed 
Lyonization (Heard and Disteche 2006). Another example of 
epigenetic regulation mediated by lncRNAs is represented by 
HOTAIR (Rinn et al. 2007) that, transcribed from the HOXC locus, 
recruits repressive complexes to silence genes in the HOXD locus 
and is the first lncRNA described acting in trans on another 
chromosome.  
LncRNAs have also been shown to be involved in mRNA stability 
and translation (Gong and Maquat 2011), in the organization of 
nuclear architecture (Mao et al. 2011) and to interfere with protein–
DNA binding (Kino et al. 2010) and directly alter protein function 
(Willingham et al. 2005). Recent studies have first suggested and 
then demonstrated that RNAs are able to influence each other levels 
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by competing for the limited pool of miRNAs (Seitz 2009, Poliseno 
et al. 2010) and open the door to a novel interpretation of the 
conventional RNA logic. According to the competing endogenous 
RNA (ceRNA) theory (Salmena et al. 2011), RNA molecules are 
able to sequester miRNAs protecting their targets from repression. 
LncRNAs have indeed shown, in accord with the ceRNA theory, 
the ability to modulate mRNA levels by competing for microRNA 
binding (Cesana et al. 2011). 
Such array of functions enhanced regulatory networks in the cell 
increasing the complexity of the system and providing an important 
evolutionary advantage to higher eukaryotes(Guttman and Rinn 
2012, Rinn and Chang 2012)  
&&
Figure 6: Mechanisms of LncRNA action. 
lncRNAs (indicated in green) have been shown to regulate gene 
expression at multiple levels: chromatin,transcription, mRNA, 
translation, and protein. Hematopoietic lncRNAs may act at any of 
these levels. “MicroRNA sponge” refers to the ability of lncRNAs to 
sequester cellular microRNAs and prevent them from binding mRNA 
target (Paralkar and Weiss 2013). 
&
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Non-coding RNAs in muscle biology 
Muscle tissue development is, as already described, a highly 
regulated process orchestrated by an evolutionary conserved 
network of transcription factors responsible of controlling the 
delicate switch between proliferation and differentiation processes 
of muscle cells. In addition to the coordinated regulation of muscle 
specific genes, the myogenic development involves the expression 
of a collection of ncRNAs, which modulate, at many levels, muscle 
development and homeostasis.  
The essential role of miRNA in muscle development has been, 
initially, demonstrated generating Dicer knock-out mutants in mice; 
this approach resulted in severe muscle defects due to the loss of 
miRNAs expressed in cardiac and skeletal muscles (O'Rourke et al. 
2007).  
Several miRNAs are, in fact, found to be specifically expressed or 
highly enriched in skeletal and/or cardiac muscles (McCarthy 
2008). Among them the most widely characterized are the members 
of the miR1/206 and miR133a/133b families, that have different 
expression profiles (figure 7). 
 
 
&
 
Figure 7: Genomic structures of muscle-specific miRNAs and 
their sequence homologies. The genomic locations of muscle-
specific miRNA genes, miR-1-1/miR-133a-2, miR-1-2/miR-133a-1, 
miR-206/miR-133b on mouse chromosomes. The expression of these 
miRNAs and the host genes in which they reside are also indicated . 
adapted from (Chen et al. 2009) 
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- miR-1-1/133a-2 and miR-1-2/133a-1 clusters, show a cardiac and 
skeletal muscle specific transcription, that is controlled by two 
separate enhancers, one upstream and the other intergenic, where 
the coordinated action of myogenic transcription factors SRF, 
MEF2, and MyoD has been reported (Zhao et al. 2005, Rao et al. 
2006, Liu et al. 2007). 
- The cluster encoding miR-206 and miR-133b is transcribed 
exclusively in skeletal muscle (Chen et al. 2006) and is 
characterized by a complex architecture in terms of transcriptional 
control: miR-206 is expressed autonomously from its own   
proximal   promoter and miR-133b instead, is transcribed from a 
13Kb distal promoter in conjunction with Linc‐MD1 (long non-
coding RNA, muscle differentiation-1). This two miRNAs also 
show a different timing of expression during the differentiation 
process; miR-206 is, in fact, already expressed in proliferating 
myoblasts, whereas miR-133b transcription is activated only upon 
differentiation (Cesana et al. 2011). 
All these miRNAs cooperate with transcription factors to 
orchestrate the precise temporal expression pattern of muscle genes. 
An example of the complex circuitry formed by them, their targets, 
MRFs and other factors involved in skeletal muscle and cardiac 
development is shown in figure 8.  
 
 
 
  
 
 
 
 
Dottorato&di&ricerca&in&Genetica&e&Biologia&Molecolare&
&
Pag&25&&
 
 
 
 
 
Figure 8 – miRNAs circuitries during skeletal muscle (A) 
and cardiac (B) development. 
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In addition to these muscle-specific miRNAs (also called myoMirs)  
a key role in the myogenesis is played by miR-31, a microRNA 
well known for his involvement in tumor methastatic progression 
(Valastyan and Weinberg 2010). 
miR-31 has another key role in muscle development; it expressed in 
muscle satellite cells and is involved in the process of regeneration, 
targeting Myf5 mRNA and preventing its accumulation in the 
quiescent pool (Crist et al. 2012). 
Our group also demonstrated that miR-31 has another important 
target, it is in fact able to repress dystrophin synthesis (Cacchiarelli 
et al. 2011).  
This discovery was possible thanks to the observation that miR-31 
is highly enriched in dystrophic condition, both in mdx mice and 
human DMD myoblasts; in particular its expression has been found 
localized in regenerating myoblasts of dystrophic muscles 
indicating that its high levels of are due to the intensive 
regeneration program which is mediated by the activation of 
satellite cells (Cacchiarelli et al. 2011). Interestingly, in dystrophic 
myoblasts and satellite cells the lack of dystrophin correlated with a 
delay of the maturation process of the cells. In the same work was 
also shown that in dystrophic conditions, when dystrophin synthesis 
is rescued through the exon skipping strategy, the inhibition of 
miR-31 activity increased dystrophin production. 
Since in a compromised muscle the contribution to dystrophin 
production by regenerating fibers is quite relevant, miR-31 
repression in this compartment can represent an improvement to 
current therapeutic treatments aimed to increase the levels of 
dystrophin synthesis.  
 
-Linc‐MD1  is one of the first muscular lncRNAs identified, 
conserved in human and mouse, with a crucial role in myogenesis 
(Cesana et al. 2011). 
Expressed with a specific timing during in-vitro differentiation of 
mouse myoblasts, Linc‐MD1 controls the progression from early to 
late phases of muscle differentiation by functioning as a ceRNA; 
competing for the binding of miR-133 and miR-135, it regulates the 
expression of mastermind-like protein 1 (MAML1) and myocyte-
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specific enhancer factor 2C (MEF2C), transcription factors with a 
key role in activating muscle genes involved in the late stages of 
muscle differentiation (figure 8c). 
This LncRNA has another important characteristic; its expression is 
found strongly reduced in DMD patients’ myoblasts. In these cells, 
the rescue of linc-MD1, produced the recovery of both MAML1 
and MEF2C synthesis and partial rescue of the correct timing of the 
differentiation program, suggesting a relevant conserved role in the 
control of muscle differentiation. 
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Figure 9 - ncRNAs in muscle differentiation.&&
A) Schematic representation of the differentiation stages of muscle 
cells and of the protein factors involved in each phase. The graph 
shows the corresponding temporal expression patterns of selected 
non-coding RNAs (ncRNAs).  
B) MicroRNAs (miRNAs) cooperating with transcription factors to 
sharpen their temporal expression pattern. miRNA that prevent the 
early activation of late myogenic proteins, such as utrophin and 
dystrophin and late myogenic miRNAs that reinforce late 
differentiation stages are indicated.  
C) Linc-MD1 reinforces the switch from early to late differentiation 
gene expression by acting as a ‘sponge’ to limit the repressive effect 
of miR-133 on Maml) and of miR-135 on Mef2c. SRF, serum 
response factor. (Fatica and Bozzoni 2014) 
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AIMS 
&
In the last two decades genome-sequencing projects in conjunction 
with transcriptomic analysis have shown that the majority of the 
genome in animals and plants is transcribed in a developmentally 
regulated manner to produce large numbers of non–protein-coding 
RNAs (ncRNAs). The number of these molecules increases with 
evolution, suggesting that RNA-based regulatory mechanisms may 
have a relevant role in the increase of developmental complexity in 
eukaryotes; It has been now widely demonstrated, that many of 
these transcripts are functional, and have important roles in 
regulating gene expression at many levels in the cell. During this 
intense RNA-era it has been discovered that, even in the muscle 
tissue, in addition to the coordinated regulation of MRFs, the 
differentiation process involves the expression of different kind of 
ncRNAs, able to modulate, at many levels, muscle development. 
My PhD project was dedicated to get a more comprehensive 
catalogue of muscle specific ncRNAs and to decipher how these 
molecules regulate gene expression and chromatin dynamics in this 
tissue development and homeostasis. Thanks to advanced high-
throughput RNA sequencing and cellular and molecular biology 
techniques I have found a set of  polyadenilated lncRNAs expressed 
in muscle and I defined their tissue specificity, subcellular 
localization and timing of expression. 
Among them I identified two lncRNAs deriving from the locus 
containing miR-31, a well characterized, microRNA that has an 
important role in the muscle differentiation process and is able to 
repress the expression of dystrophin, a protein with a key role in 
muscle fibres integrity.  
I demonstrated that these two lncRNAs, expressed at high levels in 
proliferating cells, have a different structure and a different 
localization in the intracellular compartments. Modulation of their 
expression, trough different experimental approaches, suggests that 
they could have a role in promoting the switch between 
proliferation and differentiation. 
I also examined miR-31 locus in the human genome and I found 
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expessed, as in mouse, two different lncRNAs. I finally confronted 
their levels in WT and DMD conditions, both in human cells and in 
the mdx mouse, the murine model for the pathology. 
 
&
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RESULTS  
 
Having a comprehensive view of the transcriptome, is essential to 
reveal the RNA components of cells and tissues, and also for 
understanding the molecular mechanisms involved in development 
and disease. In particular an accurate transcriptomic analysis is 
necessary to catalogue all species of transcript, including mRNAs, 
non-coding RNAs and small RNAs expressed in a model system at 
different timing during the differentiation process. 
A powerfull tool to obtain that information is represented by RNA-
Seq, an approach that, taking advantages of the recently developed 
deep-sequencing technologies, allows to sequence the entire 
population of RNA (total or fractionated, such as poly(A)+) 
extracted from cultured cells or tissues. Following sequencing, the 
resulting reads are either aligned to a reference genome or reference 
transcripts, or assembled de novo without the genomic sequence to 
produce a genome-scale transcription map that consists of both the 
transcriptional structure and/or level of expression for each gene 
(Wang et al. 2009).  
In collaboration with components of the research group where I 
worked for this thesis, I realized a RNA-Seq experiment, using 
Illumina TruSeq™ Technology, on the poli(A)+ RNA fraction 
extracted form C2C12, an immortalized cell line of murine 
myoblasts, derived from satellite cells (Yaffe and Saxel 1977, Blau 
et al. 1985), that are commonly used as an in-vitro model of skeletal 
muscle development.  
These cells are, in fact, able to differentiate into myocytes and to 
form multinuclated myotubes under appropriate culture conditions 
(see matherial and methods). 
The experiment was realized on samples obtained from cells 
collected during proliferation and after 1, 3, and 5 days from the 
induction of to the differentiation process, with the aim of 
underlining changes and modulation occurring in the trascriptome 
during the myogenesis with particular attention to the non-coding 
portion of the genome. 
Datas obtained from the RNAseq were analysed by collaborators of 
prof. Anna Tramontano and, thanks to their bioinformatics analysis 
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I obtained a list of putative, not previously annotated long non-
coding RNAs that showed a sufficient level of expression and were 
modulated during differentiation.  
We selected from the list two groups of lncRNAs, one formed by 
putative lncRNAs that appeared to be up-regulated and the other 
formed by putative lncRNAs that appeared to be down-regulated 
after the induction of differentiation . 
Characterization of putative lncRNAs expression in 
murine myoblasts 
To validate data obtained from the sequencing and to verify the 
pattern of expression during the differentiation process of the 
selcted putative lncRNAs I collected RNA samples from cultured 
proliferating C2C12, in growth medium (GM) and after 5 days from 
the induction of the differentiation process (DM).  
I used the obtained samples to perform a semi-quantitave Reverse 
Trascription Polimerase Chain Reaction (sqRT-PCR) experiment 
that allowed us to detect the RNA expression levels.  
I designed and used for the experiment, different pairs of primers 
that were designed, accordingly to the RNA-seq data, to specifically 
amplify the putative ncRNAs and results of the experiment are 
shown in Figure 10.  
Figure 10A shows lncRNAs whose expression, according to the 
sequencing experiment, is induced or strongly up-regulated after the 
switch to differentiation media. Linc-MD1, that is absent in growth 
conditions (GM) and  activated upon shift to differentiation (DM) 
of mouse myoblasts (Cesana et al. 2011), has been used as a 
positive control and GAPDH as a normalization control.  
It is interesting to notice that, in accordance with the RNA-seq data 
the expression of many of these lncRNAs is strongly up-regulated 
at day 5 of differentiation (DM). An exception is represented by the 
levels of lnc-182, lnc-082 and lnc-058, that seem to remain quite 
constant in proliferating and differentiated cells.  
I also found that two of the putative lncRNAs, lnc-405 and lnc-149 
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are present in two isoforms with different expression patterns. lnc-
405  locus, in particular, seems to produce a specific isoform in 
proliferating condition (GM) and another different one in 
differentiated cells (DM). To ascertain the specificity of the 
amplification, PCR products have been sequenced and the different 
isoforms produced from the amplification of lnc-405 and lnc-149 
resulted deriving from the correct locus.  
In Figure 10B are grouped lncRNAs whose expression should 
decrease, according to sequencing data, after the switch to 
differentiation media.  
In some cases, as for lnc-456 and lnc-686, the level of the ncRNA 
seems to remain constant in proliferating (GM) condition and in 
differentiated cells (DM); in other cases, as for lnc-254 and lnc-793, 
the level of expression is found slightly decreased in differentiated 
C2C12 (DM).  
 
 
 
 
 
  
&
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lnc-RNAs subcellular localization. 
It is known that lncRNAs can be localized in different subcellular 
compartments wherethey exert different functions (Ponting et al. 
2009). 
To further characterize the identified lncRNAs I investigated their 
subcellular localization in proliferating or differentiated C2C12 
myoblasts depending on their timing of expression. 
Using a cell fractionation procedure I was able to obtain the 
cytoplasmic, nucleoplasmic and chromatin extracts from cell 
collected in proliferating conditions (GM) or after 5 days of 
differentiation (DM).  
RNA was extracted and analysed by qRT-PCR with the same 
primers used in the characterization of their expression (Figure 10). 
To verify the correct nuceus/cytoplasmic separation I used GAPDH 
mRNA (GAPDH) as a cytoplasmic marker (C) and its pre-mRNA 
(pre-GAPDH) as a nuclear control (Chr). 
Figure 11A shows lncRNAs whose expression proved to remain 
stable while Figure 11B displays the sub-cellular localization of 
lncRNAs whose expression was induced or up-regulated upon 
differentiation. In the latter case cells were collected after 5 days 
from the induction of differentiation  (DM).  
lnc-405 and lnc-149, that have two isoforms with different 
expression patterns were analysed both in proliferating and 
differentiated cells (Figure 11A and B) . 
Notably, the lnc-149 isoforms are localized in different subcellular 
compartments (Cytoplasm and Nucleus) maintaining the same 
pattern in both proliferating (GM) and differentiated cells (DM). 
From the lnc-405 locus are produced two isoforms, one specifically 
expressed in proliferating condition (GM- Figure 10) that is found 
localized in the nucleus of C2C12 cells (GM-chr figure 11A) and 
another one specifically expressed in differentiated cells (DM-
Figure 10) that appears to be present both in the cytoplasm (C) and 
associated to the chromatin (chr) (Figure 11B) with a stronger 
signal obtained in the latter.  
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Figure 11: lncRNAs subcellular localization in C2C12 
myoblasts.  
(A) sqRT-PCR performed on RNA exctracted from cyroplasmic (C), 
nucleoplasmic (N) and Chromatinic (Chr) fraction of mouse 
myoblast in proliferating conditions (GM). GAPDH mRNA 
(GAPDH) and pre mRNA (pre-GAPDH) were used as endogenous 
controls.  
(B) sqRT-PCR performed on RNA exctracted from cyroplasmic (C), 
nucleoplasmic (N) and Chromatinic (Chr) fraction of differentiated 
mouse myoblast (DM). GAPDH mRNA (GAPDH) and pre mRNA 
(pre-GAPDH) were used as endogenous controls.  
Stars are used to indicate different isoforms   
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lnc-RNAs tissue specificity in WT and mdx mouse. 
The mdx mouse is a dystrophin-deficient mutant that has been 
widely used to study the DMD pathology. 
These mice have a shorter life span as compared to wild-type 
controls and in their muscle, show the typical degeneration 
processes associated with the pathology.  
Between the second and the sixth week of life, marked waves of 
degeneration and regeneration interest the mice muscle tissue, 
which results in an increase in the number of newly differentiating 
myofibers characterized by centralized nuclei and an increased 
heterogeneity in myofiber size. Subsequently, loss of muscle tissue 
is slowed and general muscle weakness is not evident until later in 
the life of the animals (Willmann et al. 2009). 
I chose to analyse the expression of our lncRNAs in different 
muscular tissues obtained form 6 weeks old mdx and wt mice; I 
chose that age because, in that period, in mdx mice the degeneration 
and regeneration process are already occurring and it is possible to 
observe a great number of newly differentiating myofibers 
characterized by centralized nuclei and an increased heterogeneity 
in myofiber size. Moreover I wanted to assess if our lncRNAs were 
expressed only in muscle, showing tissue specificity, or if their 
expression could be detected in other district of the mice body. 
In order to do that, Mdx mice were sacrificed in parallel with wild-
type (WT) isogenic/aged matched animals. Different muscular 
districts (gastrocnemius, heart and tibialis) were dissected alongside 
with non-muscular one (Brain, Cerebellum and Lung); total RNA 
was extracted from powered tissues (see material and methods) and 
used for a sqRT-PCR experiment performed with the same primer 
pairs used for the characterization of the lncRNAs expression in 
C2C12 cells (Figure 10) 
The results are shown in figure 12. 
Several lncRNAs showed a muscle specific expression; in particular 
lnc-267, lnc-994 are expressed at high levels in skeletal muscle, 
slightly up-regulated in mdx condition. In contrast lnc-996, lnc-049, 
and both isoforms of lnc-149 are only found to be expressed in mdx 
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skeletal muscle resulting almost absent in WT mice and in heart, 
brain, cerebellum and lung of both mdx and WT animals. 
Once again, the expression profile of lnc-405 appears to be very 
interesting; the two isoforms seem to have a very precise expression 
pattern. One of them has a muscle-specific expression and is found 
both in skeletal muscle and in the heart; the other one is found in 
non-muscular tissues, brain, cerebellum and lung. Neither of them 
seems to vary between wt and mdx conditions. 
In addition to the already mentioned lncRNAs, I found other 
lncRNAs that do not have a tissue specific expression but that are, 
instead, deregulated in mdx conditions; an example of that is 
represented by lnc-666 that in WT skeletal muscle is not expressed 
while it is present in the same tissues derived from the mdx mice. 
Finally there are lncRNAs that have a very low level of expression 
in adult mice: lnc-023 and lnc-793 are good examples. These data 
confirm the decrement in their expression revealed in the 
sequencing experiment and confirmed our sqRT-PCR in C2C12 in-
vitro differentiation. 
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Figure 12: lnc-RNAs tissue specificity in WT and mdx mouse. 
sqRT-PCR performed on total RNA exctracted from 6 weeks old  
WT and mdx mice Brain (BRA), Cerebellum (CRB), Gastrocnemius 
(GAS), Heart (HRT), Lung (LUN) and tibialis (TIB). Lnc-RNAs are 
grouped according to their expression pattern. 
GAPDH mRNA (GAPDH) was used as endogenous controls. 
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Characterization of a new lncRNA arising from miR-
31 locus in mouse.  
Data obtained from the RNAseq indicated a putative ncRNA 
transcript arising from miR-31 genetic locus. This transcript, even if 
didn’t seemed to be expressed at high level, caught our attention; 
miR-31, in fact, expressed from the same locus, has a key role in 
muscle cells since it targets Myf5 and dystrophin mRNA 
(Cacchiarelli et al. 2011, Crist et al. 2012) and his levels have been 
found to be higher in dystrophic conditions, in both mouse and 
human biopsies. 
Previous studies by Hong and colleagues (Sun et al. 2009) showed 
that in mouse miR-31 is transcribed from a single locus in the 4th 
chromosome. This locus (chr4:88,556,461-88,556,566) is formed 
by 3 non-coding exons and the miRNA is hosted in the third one. 
To confirm our RNA-seq data and this genomic organization we 
performed an advanced 5’ rapid amplification of cDNA end 
(5’RACE) assay able to select for 5’end capped RNAs using RNA 
extracted form proliferating C2C12 murine myoblasts.  
Our analysis revealed the presence of two different transcripts. 
The first one has a Trascriptional Start Site (TSS), indicated by an 
arrow in figure 13, located ≅30Kb upstream pre-miR-31 and is 
formed by the three predicted exons.  
The second isoform previously not annotated, has a TSS, indicated 
by an arrow, that maps 750bp upstream pre-miR-31 figure 13.  
When performing the RACE experiment, first strand cDNA was 
synthesized from RNA using oligo-dT and considering this and also 
according to the RNA-seq data it is possible to conclude that both 
transcripts are polyadenilated. The two isoforms were named linc-
31D (Distal) and linc-31P (Proximal) based on TSS position from 
pre-miR-31. Both linc-31D and linc-31P contain the pre-miR-31 
sequence. 
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Figure 13: linc31 genomic structure.  
Upper panel shows the schematic representation of the murine miR-
31 genomic locus and the transcriptional start sites (TSS) found by 
‘5 RACE analysis indicated by arrows. The electropherograms 
highlight the 5’ sequences of the two linc31 isoforms (LINC31 
Distal and LINC31 Proximal). 
Lower panel shows the schematic representation of LINC31 Distal 
and LINC31 Proximal transcripts containing miR-31 sequence. 
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linc-31 expression is modulated during in vitro muscle 
differentiation. 
Our group has already demonstrated that miR-31 level is high in 
proliferating myoblasts and then decrease upon the induction of 
differentiation (Cacchiarelli et al. 2011). I wanted to analyse the 
expression of the two transcripts and to compare their levels in 
C2C12 myoblasts in proliferation and during the differentiation 
process. RNA was obtained from cultured cells collected in growth 
medium (GM) and after 1, 3 and 5 days from the induction of the 
differentiation process. sqRT-PCR  was performed using specific 
primers that are able to discriminate between the two Linc-31 
isoforms.  In particular I used forward common primer, annealing to 
exon-1 of both isoforms and two specific reverse primers anneling 
or on the Distal isoform or on the Proximal one. I designed these 
primers to obtain two different-sized specific bands that allow us to 
co-amplify and discriminate between the two isoforms. 
figure 14 highlights that both linc-31D and linc-31P are expressed 
in proliferating cells and even if they are still expressed one day 
after the induction of the differentiation process, their levels 
decrease with the progression of the myogenesis. Their expression 
parallels that of miR-31’s one, that was analysed by Northern blot 
(figure 14-lower panel), to confirm the expected expression pattern, 
in the same cells (Cacchiarelli et al. 2011). Similarly to linc-31D 
and linc-31P, miR-31 levels are high in proliferating conditions 
(GM) and gradually decrease after the induction of the in-vitro 
differentiation process. 
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Figure 14: Linc-31 expression profile during an in-vitro muscle 
differentiation.  
RNA samples collected from myoblast in proliferating conditions 
(GM) and after 1, 3 or 5 days from the induction of the 
differentiation process were used to analyse linc-31 a miR-31 
levels. 
The expression pattern of the two transcripts (linc-31D and linc-
31P) originating from miR-31 locus has been analized by sqRT-
PCR,  GAPDH mRNA (GAPDH) was used as normalization control 
(upper panel).  
 miR-31 expression level in the same cells, has been analysed by 
Northern Blot.  U2 snRNA is used as endogenous control (lower 
panel). 
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linc-31P and linc-31D subcellular localization 
As for our collection of ncRNAs we wanted to investigate the 
subcellular localization of linc-31D and linc-31P isoforms. Using a 
cell fractionation procedure I was able to obtain the cytoplasmic, 
nucleplasmic and chromatin exctracts from C2C12 cells collected 
while proliferating. I proceed to RNA extraction and to sqRT-PCR 
with the same primers used for the characterization of the lncRNAs 
isoforms (figure 10). 
The panel in figure 15 shows that the two isoforms have a different 
localization: the proximal transcript (linc-31P) is not exported in the 
cytoplasm but is instead localized in the nucleus and, in particular, 
it resulted associated with the chromatin (CHR).  
Linc-31D isoform instead, seems to be exported and localized in the 
cytoplasm (CYT). 
To confirm these data, Fluorescence In Situ Hybridization (FISH) 
was then performed in proliferating C2C12 myoblasts.  
Digoxigenin (DIG)-conjugated Locked Nucleic Acid (LNA) probes 
designed to specifically recognize either Linc-31D or Linc-31P 
were utilized. 
Linc-31D fluorescence appeared diffusely and weakly staining the 
cytoplasm while the linc-31P isoform instead showed multiple and 
strong foci localized in the nucleus of proliferating cells while being 
absent after differentiation (Figure 16) 
Therefore, the FISH experiment confirmed the data obtained by 
sqRT-PCR.  
Background signals were obtained using a scramble sequenced 
probe (scramble) and another control LNA probe targeting a region 
upstream linc-31P TSS (INTRON).  
A probe targeting U6 small nuclear RNA (snRNA) has been used to 
obtain a signal that represents our positive control.  
Background signals were obtained using a scramble sequenced 
probe (scramble) and another control LNA probe targeting a region 
upstream linc-31P TSS (INTRON).  
A probe targeting U6 small nuclear RNA (snRNA) has been used to 
obtain a signal that represents our positive control.  
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Figure 15: subcellular localization of linc-31 isoforms in C2C12 
myoblasts.  
sqRT-PCR performed on RNA exctracted from cyroplasmic (C), 
nucleoplasmic (N) and Chromatinic (Chr) fraction of mouse 
myoblast in proliferating conditions (GM) to analyze linc-31D and 
linc-31P subcellular localization. GAPDH mRNA (GAPDH) was 
used as endogenous controls.  
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Figure 16: Linc-31P Subcellular localization 
Fluoresce in-situ hibridization (FISH) analysis on mouse myoblast 
in proliferating conditions (GM) and after 5 days of differentiation 
(DM) performed with Digossigenin labelled LNA probes for linc-
31P (Linc31-p). White arrows underlines the presence of linc-31P 
foci in the nucleus. 
 A scramble sequenced LNA probe (scramble) and a LNA-probe 
targeting a region upstream linc-31P TSS (INTRON) have been 
used to detect background signals.  
A probe targeting U6 small-nuclear RNA (U6) has been used to 
obtain a nuclear signal as positive control.  
Original magnification 40x,  scale bar = 20μm 
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Modulation of linc-31 affects in-vitro C2C12 
differentiation. 
Linc-31 levels are high in proliferating cells and start to decrease 
upon the induction of the differentiation process (figure 10). 
Observing that behaviour that parallels miR-31 expression, we 
hypothesized a role for our lncRNA in the transition from a 
proliferation to a differentiation stage. 
In order to confirm our hypothesis we decided to modulate its 
expression through RNA interference and through overexpression 
experiments in the C2C12 model system. To focus our attention on 
the transition, both approaches were realized collecting samples 
from cells in proliferating condition (GM) and after 1, 2 and 3 days 
from the induction of the differentiation process. 
Figure 17 shows the expression profile of two myogenic proteins, 
myogenin and MyoD (MYOG and Myod) during in-vitro  
differentiation of C2C12 cells. The expression of these proteins was 
selected to test the effects of linc-31 modulation on the progression 
of myogenesis. 
To obtain the ectopic expression of linc-31D, the cytoplasmic 
isoform, I realized a construct (Plinc31-D-ΔDrosha figure 18A) 
mutated in the miR-31 flanking region to prevent the Drosha 
cleavage of our isoform and miR-31 release. This construct ensures 
that the effects that we could observe in the myogenesis are due 
only to the lncRNA overexpression and not to high levels of miR-
31 that could be produced by the processing of our construct.  
We verified our construct effectiveness transfecting in C2C12 cells  
both our mutated construct (Plinc31-D-ΔDrosha) and a non-
mutated control construct (Plinc31-D) expressing linc-31 (Figure 
18A). 
As shown in Figure 18B sqRT-PCR analysis revealed that both 
constructs are able to produce linc-31D while the levels of miR-
31produced from Plinc31-D-ΔDrosha are significantly lower 
compared to the control  construct.  
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Figure 17: Analysis of muscle differentiation markers in C2C12 
cells. 
Protein samples were extracted from myoblasts in proliferation 
(GM) and after shift to differentiation medium for the indicated 
times. The panel shows a western blot analysis for myogenin 
(MyoG), myoD, and Actinin as a loading control. 
 
 
 
Figure 18: Linc-31P overexpression construct analysis.  
A) Schematic representation of the over-expression constructs.  
B) RNA samples were collected from myoblast transfected with 
Plinc31-D and Plinc31-D-ΔDrosha. The upper panel shows 
linc-31D overexpression analized by sqRT-PCR. GAPDH mRNA 
(GAPDH) was used as normalization control. Lower panel 
shows  miR-31 expression level in the same cells, analysed by 
Northern Blot.  U2 snRNA is used as endogenous control 
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Once verified that the effects that we could observe in the 
myogenesis are due only to the lncRNA overexpression, we 
transfected C2C12 cells and collected RNA and protein samples 
from proliferating cells (GM) (36h post-transfection) and after 1, 2, 
and 3 from the induction of the differentiation process.  
Figure 19A shows the relative quantification of linc-31D produced 
in C2C12 after the transfection of Plinc31-D-ΔDrosha (Lnc31-DΔ) 
or an empty vector (ctrl). 
Figure 19B indicates the levels of myogenin and myoD both in 
control cells and cell overexpressing linc-31D (Lnc31-DΔ). It can be 
visualized that linc-31D over-dosage has no effect on myogenin and 
MyoD expression at day 1 of differentiation when their level is still 
low (figure 19B day 1). However at day 3 and 5, linc-31D 
overexpressing cells (Lnc31-DΔ), show a 30% decreased levels of 
myogenic markers of compared to control cells (ctrl).  
To perform the RNA interference experiment I used a siRNA that 
specifically targets the linc-31D isoform (si-lnc31D) and, as 
control, a scrambled siRNA (ctrl). Even in this case we transfected 
C2C12 cells and collected RNA and protein samples from 
proliferating cells (GM) (36h post-transfection) and after 1, 2, and 3 
from the induction of the differentiation process. 
The relative quantification of linc-31D levels is presented in figure 
20A showing that a reduction of more than 60% in linc31-D levels 
in grow condition (si-lnc31D - GM) was obtained. 
The left panel (figure 20B) shows that, the reduction of linc-31D 
levels by RNA interference (si-lnc31D) upon differentiation 
anticipates the appearance of myogenin and MyoD markers at day 1 
and increases their accumulation at later stages with respect to 
control cells (ctrl). 
Overall, these results are consistent with the hypothesis that linc-31 
might have a role in regulating the transition from proliferation to 
differentiation. 
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Figure 19: Modulation of Linc-31 affects myogenesis 
linc-31D overexpression was obtained by transfection of Plinc31-
D-ΔDrosha (plinc31-DΔ) construct together with an empty control 
vector (Ctrl). Protein and RNA samples were extracted from 
myoblasts in proliferation (GM) and after shift to differentiation 
medium for the indicated times. 
A) The graph displays the levels of linc31-D, normalized for 
GAPDH, measured by qRT-PCR. Data are shown with respect to 
control experiments in grow medium set to a value of 1. Data are 
shown as mean ± SD 
B) The graphs displays the values derived from densitometric 
analysis of western blot experiments to detect myogenin (upper 
graph) and MyoD (lower graph) levels. 
Values are normalized for Actinin and are reported with respect to 
the control sample in grow medium set to a value of 1. Data are 
shown as mean ± SD 
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Figure 20: Modulation of Linc-31 affects myogenesis 
linc-31D depletion was obtained by transfection in C2C12 cells of a 
siRNA, specifc for the distal isoform, (si-linc31-D)  together with an 
scramble sequenced control siRNA (Ctrl). Protein and RNA 
samples were extracted from myoblasts in proliferation (GM) and 
after shift to differentiation medium for the indicated times. 
A) The graph displays the levels of linc31-D, normalized for 
GAPDH, measured by qRT-PCR. Data are shown with respect to 
control experiments in grow medium set to a value of 1. Data are 
shown as mean ± SD 
B) The graphs displays the values derived from densitometric 
analysis of western blot experiments to detect myogenin (upper 
graph) and MyoD (lower graph) levels. 
Values are normalized for Actinin and are reported with respect to 
the control sample in grow medium set to a value of 1. Data are 
shown as mean ± SD 
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Linc-31 expression in WT and mdx mouse muscle 
tissue 
Afterward I analysed the expression of linc-31 in the mdx the 
dystrophin-deficient model mouse to understand if, as many other 
ncRNAs and miR31(Cacchiarelli et al. 2011), its expression is 
enriched in DMD pathology. I chose to compare its expression in 
mdx and WT mice, sacrificed at 6 weeks of age. Four mdx mice 
were sacrificed in parallel with wild type (WT) isogenic/aged 
matched animals. 
 Different muscular districts were dissected and we collected RNA 
samples from gastrocnemii derived from WT and mdx animals.  
A sqRT-PCR experiment was performed on the samples using 
specific primers that are able to discriminate between the two Linc-
31 isoforms. Figure 21A indicates clearly that there is a strong 
enrichment of this RNA in mdx muscle, and that alterated levels of 
expression can be observed for both isoforms. Figure 21B shows 
the mean level of expression of Linc31P and Linc31D in WT and 
mdx, obtained by densitometric analysis, normalized for GAPDH. 
Linc31D resulted almost 3 times more expressed in the mdx tissue 
compared to the WT control; Linc31P resulted even more enriched 
and its level resulted 7 times higher in the mdx mice. Considering 
the high number of regenerating fibers present at 6 weeks of life in 
the mdx mouse model, the high levels of linc-31 are consistent with 
the hypothesis that it might have a role in regulating the transition 
from proliferation to differentiation in myotubes. 
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Figure 21: Linc-31 expression in WT and mdx mouse muscle 
tissue. 
A) linc-31D and linc-31P levels were analysed by sqRT-PCR 
performed on total RNA exctracted from 6 weeks old  WT and mdx 
Gastrocnemius. GAPDH mRNA (GAPDH) was used as 
normalization control. 
B) The graphs displays the mean values derived from densitometric 
analysis of sqRT-PCR in (A) Values are normalized for GAPDH 
and are reported with respect to the mean value of the WT samples 
set to a value of 1. 
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Linc-31 expression in human myoblasts 
A 2009 study has predicted miR-31 to be transcribed from within 
the first intron of a host gene, LOC554202, on human chromosome 
9 (Corcoran et al. 2009). In-silico analyses have confirmed these 
findings and suggest that LOC554202, which is formed by 4 non-
coding exons, could be transcribed into a long non-coding RNA and 
may have two different transcriptional start sites (Augoff et al. 
2012) (Figure 22A). The architecture of the locus is not conserved 
in structure between human and mouse and in the human genome, 
the miRNA is localized in an intronic portion of the host gene. We 
have nevertheless demonstrated that there is correspondence in 
miR-31 expression pattern in murine and human myoblast in vitro 
differentiation (Cacchiarelli et al. 2011), hence I decided to analyse 
the expression profile of LOC554202 looking for its role in 
myogenesis.  
I analysed the levels of expression by sqRT-PCR on RNA obtained 
from in vitro cultured myoblasts derived from healthy donors (WT) 
and DMD patients looking for the two putative transcripts. I 
collected the samples from proliferating cells (GM) and after 1,3 
and 5 days from induction of differentiation. Interestingly I 
identified two different isoforms (figure 22B) named Proximal and 
Distal, depending on their 5’ distance from the pri-miR31 sequence. 
Both are expressed, as in the mouse, at high levels in WT and DMD 
myoblasts in proliferating conditions (GM) (figure 23A). 
Upon induction of differentiation linc31-D expression slowly 
decreases in WT cells but remains quite high in DMD conditions.  
Linc31-P levels in WT cells, start to decrease at day 1 and almost 
disappear after 5 days from the induction of differentiation.  
In DMD conditions linc-31P levels don't vary at day 1 and remain 
higher than in control cells with only a slight decrement between 
day 3 and 5 (figure 23A). Notably, this expression pattern parallels 
miR-31 expression in the same cells (figure 23B) 
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Figure 22: linc31 genomic structure in human. 
A) Schematic representation of the human miR-31 genomic 
locus.  The putative transcriptional start sites (TSS) are 
indicated by arrows 
B) Schematic representation of LINC31 Proximal (containing 
miR-31 sequence) and LINC31 Distal transcripts in human 
cells 
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Figure 23: Linc-31 expression in human myoblasts 
A) linc-31D and linc-31P levels were analysed by sqRT-PCR 
performed on total RNA exctracted from WT and DMD 
myoblasts in proliferation (GM) and after shift to 
differentiation medium for the indicated times. GAPDH mRNA 
(GAPDH) was used as normalization control 
B) qRT-PCR of miR-31 relative expression in human primary 
myoblasts from healthy donors (WT, black bars) or DMD 
patients (DMD, White bars) in growth medium (GM) and at the 
indicated time points after shift to differentiation medium. 
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DISCUSSION 
&
The process of generating muscle fibers, also called myogenesis, is 
a perfectly orchestrated and continuous mechanism that leads to the 
formation of a multinucleated myofibers capable of contraction.  
Myogenesis can be divided into several phases characterized by the 
expression of muscle specific transcription factors known as 
myogenic regulatory factors (MRFs) that control the production of 
developmental stage-specific transcripts. For many years, the 
attention has been focused only on protein factors, especially MyoD 
(Ishibashi et al. 2005, Tapscott 2005, Cao et al. 2006), Myf5 
(Ishibashi et al. 2005), Myogenin (Cao et al. 2006) and Mrf4 
(Kassar-Duchossoy et al. 2004),  for their ability to control the 
conversion of precursor cells into  terminally differentiated muscle 
fibers (Braun et al. 1989, Edmondson and Olson 1989, Rhodes and 
Konieczny 1989).  
Recently, the scientific community focused its attention on the 
RNA world; genome-sequencing projects in conjunction with 
transcriptomic analysis have shown that the majority of the genome 
in animals and plants is transcribed in a developmentally regulated 
manner to produce large numbers of non–protein-coding RNAs 
(ncRNAs). The number of these molecules increases with 
developmental complexity, suggesting that RNA-based regulatory 
mechanisms may have a relevant role in the evolution of 
developmental complexity in eukaryotes (Mattick 2011, Nagano 
and Fraser 2011). It has been now widely demonstrated, that these 
transcripts could be functional, and have important roles in 
regulating gene expression at many levels in the cell.  
During this intense new RNA-era it has been discovered that, in 
addition to the coordinated regulation of MRFs, myogenesis also 
involves the expression of a collection of ncRNAs, able to 
modulate, at many levels, muscle development and homeostasis.  
In particular our group identified several non-coding RNAs 
(ncRNAs) with a specific role in both muscle differentiation and 
muscle degenerative pathologies. Among them we studied a micro-
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RNA, miR-31, that we found expressed at higher levels in muscle 
affected by Duchenne muscular dystrophy (DMD).  
It is also known that this microRNA is expressed in muscle satellite 
cells targeting myf5 (Crist et al. 2012) but we were able to 
demonstrate the importance of this miRNA in the differentiation 
process and its ability to repress, by targeting its 3’ untranslated 
region, the expression of Dystrophin, a protein that has a key role in 
muscle fibres contraction and integrity (Cacchiarelli et al. 2011). 
Moreover we found that miR-31 could be considered a new 
therapeutic target in DMD because we demonstrated that its 
modulation enhances our U1snRNA-based exon skipping approach.  
Recently, our group also discovered a long non-coding RNA 
(lncRNA), named linc-MD1, acting as a ceRNA in muscle cells, 
cross-regulating specific mRNAs by competing for miRNA binding 
via their miRNA recognition motifs (Cesana et al. 2011). 
Except few examples, as linc-MD1, there aren’t many annotated 
lncRNAs identified as myogenic regulators so far, and I decided to 
focus my efforts to get a more comprehensive catalogue of muscle 
specific lncRNAs and to decipher how these molecules regulate 
gene expression and chromatin dynamics in this tissue development 
and homeostasis. 
I profiled C2C12 mouse myoblast transcriptome by NGS during 
proliferation and at different stages of differentiation and I was able 
to identify, thanks to bioinformatics analysis, a set of non-
annotated, polyadenylated putative long non coding RNAs varying 
their expression during myoblast differentiation, with most of them 
being up-regulated in myotubes.  
I confirmed their existence in C2C12 myoblasts, and studied their 
expression pattern both in proliferating and differentiated muscle 
cells and discovered, for some of them, as lnc-405 different 
transcriptional isoforms. Since it is known that lncRNAs can be 
localized in different cellular compartment and that, depending on 
that localization, they can exert different functions in several 
molecular mechanisms in the cell (Ponting et al. 2009), before 
starting a phenotypic analysis resulting from their modulation I 
investigated their localization inside the cell. I identified many 
lncRNAs with a specific nuclear localization; we can hypothesize 
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for them a function, as per many nuclear long noncoding RNAs, in 
guiding chromatin modifiers to specific genomic loci. There are, in 
fact evidence, that these molecule are able to recruit DNA and 
histones methyltransferase and histone modifiers, to mediate 
transcriptional repression through the formation of silent 
heterochromatine (Rinn et al. 2007, Nagano et al. 2008, Zhao et al. 
2008). On the other hand they can mediate transcriptional activation 
recruiting chromatin-modifying complexes able to change the three-
dimensional architecture of the chromatin (Wang et al. 2011).  
To further increase the complexity, it is know that these noncoding 
transcripts can execute their function on the genome acting both in 
cis and in trans (Rinn and Chang 2012). 
Finally lncRNAs can also have indirect regulatory effects on many 
different genes, by acting as decoys that sequester transcription 
factors (Sun et al. 2013) in the nucleus.  
In addition to nuclear lncRNAs I found many other molecules 
localized in the cytoplasm where they could have a wide array of 
possible roles. lncRNAs have been described to modulate mRNA 
stability both increasing (Kretz et al. 2013) or decreasing their 
stability (Gong and Maquat 2011).  
They can also regulate translation by direct base-pairing, in some 
described cases enhancing it (Carrieri et al. 2012), in other blocking  
it (Yoon et al. 2012). Finally they could act as ceRNAs (Cesana et 
al. 2011, Salmena et al. 2011) binding to and sequestering specific 
miRNAs, to protect their target mRNAs from repression.  
I also wanted to asses if the lncRNAs characterized were expressed 
only in muscle cells and whether their expression changed in WT 
versus Duchenne conditions; I found that many of them had a 
muscle specific expression, (lnc-267, lnc-994) and that others  (lnc-
996, lnc-049, both isoforms of lnc-149) are expressed in mdx 
skeletal muscles and almost absent in WT mice. 
In addition to this new collection of lncRNA,  data obtained from 
the RNAseq showed a putative ncRNA transcript, that, even if not 
expressed at high levels, caught our attention, being it transcribed 
from miR-31 genetic locus. 
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I showed the existence of two different transcript originating form 
this locus and I named them linc-31D (Distal) and linc-31P 
(Proximal) based on TSS position from pre-miR-31. 
Both linc-31D and linc-31P contain the pre-miR-31 sequence. 
Furthermore, both of them resulted upregulated in proliferating 
muscle cells and decreased with the progression of the myogenesis, 
paralleling miR-31 expression.  
The two isoforms have a different localization: the proximal 
transcript (linc-31P) is not exported in the cytoplasm but is instead 
localized in the nucleus and, in particular, it resulted associated with 
the chromatin, linc-31D isoform instead, is localized in the 
cytoplasm.  
As far as the function of linc-31D is concerned, we showed that its 
modulation impinged on myogenesis. linc-31D overexpression in 
mouse myoblasts, in fact, produced a decrease in the accumulation 
of myogenic markers, Myogenin and MyoD, while its RNAi-
dependent downregulation led to  their increase.&
Overall these findings suggest that linc-31D might have a role in 
regulating the transition from proliferation to differentiation .  
I also analysed the expression of linc-31 in the mdx mouse skeletal 
muscles, to understand if, as many other ncRNAs and miR31 
(Cacchiarelli et al. 2011), its expression is enriched in DMD 
pathology. I confirmed that both isoforms are enriched in DMD 
conditions and, considering the high number of regenerating fibers 
present in the mdx mouse model, the high levels of linc-31 are 
consistent with our hypothesis that it might have a role in regulating 
the exit from the proliferative state.  
The architecture of the locus is not conserved in structure between 
human and mouse and in the human genome, miR-31 is localized in 
an intronic portion of a host gene with 4 predicted non-coding 
exons but I demonstrated that as in mouse, in human myoblasts 
derived from healthy donors (WT) and DMD patients there are two 
different non-coding isoforms transcribed form the locus and I also 
found them expressed, as in mouse, at high levels in proliferating 
conditions both in WT and DMD myoblasts. Upon the induction of 
the differentiation process I detected a decrease in the two isoforms’ 
levels in WT cells. The lncRNAs levels remains quite high in DMD 
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conditions corroborating, once again, our hypothesis of their role in 
regulating the exit from the proliferative state.  
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MATERIALS AND METHODS 
 
 
Cell Cultures and Treatments. 
C2C12 myoblasts were cultured in growth medium (DMEM high 
glucose, 2x glutamine, 1X Penicillin/Streptomycin 20% fetal bovine 
serum). Myogenic differentiation is initiated upon reaching 
confluence by switching the cells to differentiation medium 
(DMEM high glucose,  2x glutamine, 1X Penicillin/Streptomycin, 
2% horse serum)  
Cells were transfected with plasmid DNA using lipofectamine-2000 
(Invitrogen).  
siRNA molecules designed against linc-31D were transfected using 
HiPerfect (QIAGEN). All transfections were performed in grow 
medium according to manufacturer’s specifications.  
Control and Duchenne primary myoblasts carrying exon 44 deletion 
(WT-9808 and Δ44-9981 ) were obtained from the Telethon 
Neuromuscular Biobank and were first pre-plated in order to 
separate fibroblasts from the primary line, then seeded in Human 
Skeletal Muscle Growth Medium (PromoCell, Haidelberg, 
Germany). 
All cell culture are grown in a humidified incubator, at 5% CO2 and 
37°C.  
 
Overexpression constructs. 
 Constructs for the over-expression of linc-31D was obtained by 
cloning linc-31D cDNA in pCDNA3.1- plasmid (Invitrogen) and 
the mutant  linc-31D-ΔDrosha was obtained by inverse PCR on the 
first construct. 
 
RACE analysis:  
5’ RACE analyses were performed using 5' RACE System for 
Rapid Amplification of cDNA Ends (invitrogen) choosing reverse 
primers surrounding pre-miRNA sequences.  
cDNA synthesis, PCR and nested-PCR were performed according 
to manufacturer’s specifications. 
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Western blot analysis:  
Western blot analyses were carried out as previously described 
(Incitti et al. 2010). Primary antibodies: anti-myogenin (MyoG sc-
12732, 1:1,000 in TBST); anti-MyoD (DAKO, Glostrup, Denmark, 
1:500 in 3% milk); anti-actinin (ACTN sc-15335, 1:1000 in TBST). 
Secondary antibodies: ImmunoPure Goat Anti-Rabbit IgG 
Peroxidase-Conjugated (Pierce, Rockford, IL, 1:5,000 in 5% milk); 
ImmunoPure®Goat Anti-Mouse IgG Peroxidase Conjugated 
(Pierce, 1:10,000 in 5% milk); donkey anti-goat IgG-HRP (sc-2020, 
diluted 1:5,000 in 3% milk). 
 
RNA preparation and analysis:  
Total RNA was prepared from Cells harvested with and liquid 
nitrogen powdered tissues homogenized in1 ml of QIAzol Lysis 
Reagent (Qiagen). RNAs were extracted by miRNeasy (Qiagen), 
following manufacturer's specifications; concentration was assessed 
with Nanodrop ND-1000 Spectrophotometer (CELBIO; Pero, 
Milan, Italy).  
qRT-PCR were performed using miScript System (Qiagen™). 
sqRT-PCR was performed using SuperScript® III First-Strand 
Synthesis System (Invitrogen™) and MyTaqTM Hot-Start DNA 
Polymerase  (Bioline). 
Primers sequences are available on request. 
Northern blots for miRNAs were performed according to 
Cacchiarelli et al. (2010) using LNA detection probes (Exiqon). 
 
In situ hybridization to interphase nuclei 
C2C12 cells were seeded onto polylisinated coverslips and fixed in 
2% PFA in PBS for 20 min at 4°C. Cells were firstable 
permeabilized in 0,5% Triton X-100/2 mM VRC/PBS on ice for 10 
min, and then rinsed in 2X SSC prior to hybridization. 
Hybridization was carried out using custom DIG conjugated-LNA 
probe (Exiqon) in moist chambre at 53°C for 1 h.  
In situ hybridization on DIG-labelled probe was performed with 
fluorescent monoclonal anti-Digossigenin antibody 
(JacksonImmunoResearch).  
Coverslips were then washed, mounted with Vectashield (Vector 
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lab) mounting medium. 
 
The sequence of the probe utilized are:  
U6: CACGAATTTGCGTGTCATCCTT 
INTRON: TAACAGTGCAACAGAGCTACA 
LINC31: AATGCAGTGGTCCTTAGAGTGT 
SCRAMBLE: GTGTAACACGTCTATACGCCCA 
 
 
Image acquisition and analysis: 
For examination was used Zeiss AxioObserver A1 inverted 
fluorescence microscope equipped with Axiocam MRM R camera 
and Plan-Neofluar EC 10X/0,3 M27 and LD 40X/0,6 M27 
objectives. The images were acquired with AxioVision Rel.4.8 
imaging software. 
 
 
Statistical analyses:  
Each data shown in histograms is the result of at least three 
independent experiments performed on at least three different 
samples/animals. Data are shown as mean ± standard deviation. 
Unless specifically stated, statistical significance of differences 
between means was assessed by two-tailed t-test and a p < 0.05 was 
considered significant. 
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